Compare Koninklijke Philips NV (PHG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Koninklijke Philips NV vs TG Therapeutics Inc — how do they compare? Koninklijke Philips NV trades at $24.22 (market cap $23.52B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Koninklijke Philips NV is far larger — about 2.9× TG Therapeutics Inc's market cap, and Koninklijke Philips NV pays a 4.17% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Koninklijke Philips NV for 84 Days and TG Therapeutics Inc for 16 Days on average.
| PHG | TGTX | |
|---|---|---|
Market Cap | $23.52B | $8.16B |
Volume | 1,635,069 | 1,735,121 |
Sector | Health | Health |
52-Week High | $32.91 | $59.06 |
52-Week Low | $23.81 | $26.94 |
Typical Hold Time | 84 Days | 16 Days |
Enterprise Value | $29.87B | $8.37B |
Dividend Yield | 4.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PHG trades at $24.24, up 0.62% today, amid a bearish technical signal from moving averages. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Recent financials show a return to profitability in 2025 with net income of $895 million, while cash flow from operations remains positive at $1.17 billion. Key developments include new product launches in healthcare imaging and a $33.7 million ARPA-H award for AI-enabled stroke care.
The outlook is mixed: strong earnings momentum and solid profitability metrics support upside, but technical weakness and a high 'Hold' analyst consensus suggest near-term caution. Risks include competitive pressures and debt levels, though institutional buying activity indicates underlying confidence.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
